Good-Heart6425
GLP-1 Enthusiast
Our next set of Demystifying Medicine presentations will be on GLP-1, from lab discovery to blockbuster therapy for obesity, diabetes, and perhaps other health conditions.
Our speakers are Svetlana Mojsov, Ph.D. (Rockefeller) and Yaron Rotman, M.D. (NIH/NIDDK). The presentations are TODAY , remote-only and viewable at the time of the event via https://videocast.nih.gov <https://videocast.nih.gov/> and then archived. **
This session will discuss the remarkable scientific arc of GLP-1, from early efforts to understand gut peptides and glucagon biology, to the identification of the biologically active GLP-1(7-37) sequence as a 31–amino acid incretin with therapeutic potential, to the modern development of GLP-1 receptor agonists as transformative treatments. We will begin by describing foundational work defining active GLP-1 and establishing its insulin-stimulating properties, placing the discoveries in the broader context of incretin biology. Then will address the urgent need for effective therapies for metabolic dysfunction–associated steatohepatitis (MASH), the rationale for using GLP-1 receptor agonists in this disease, key benefits and concerns in clinical use, and ongoing NIH studies aimed at understanding mechanisms of action and predictors of response.
Together, the speakers hope the audience will gain a clear understanding of how fundamental peptide biochemistry led to one of the most consequential therapeutic classes in modern medicine—and what important mechanistic and clinical questions remain.
Svetlana Mojsov <https://www.rockefeller.edu/our-scientists/research-affiliates/1055-svetlana-mojsov/> is the Lulu Chow Wang and Robin Chemers Neustein Research Associate Professor at The Rockefeller University. A recipient of the Breakthrough Prize in Life Sciences (2025) and Lasker-DeBakey Clinical Medical Research Award (2024), Mojsov has been central to identifying the biologically active form of GLP-1, GLP-1(7-37), and demonstrating its role as an incretin capable of stimulating insulin secretion. Her discoveries laid critical groundwork for the development of GLP-1–based therapies for type 2 diabetes and obesity.
Yaron Rotman <https://irp.nih.gov/pi/yaron-rotman> is an NIH senior investigator and chief of the Liver & Energy Metabolism Section in the NIDDK Liver Diseases Branch and an attending hepatologist at the NIH Clinical Center. His research focuses on mechanistic and translational studies of metabolic dysfunction–associated steatotic liver disease, using clinical trials, human genetics, and experimental models to uncover pathways of hepatic fat accumulation and injury.
With speakers like this, as always, be prepared to be dazzled and demystified
Our speakers are Svetlana Mojsov, Ph.D. (Rockefeller) and Yaron Rotman, M.D. (NIH/NIDDK). The presentations are TODAY , remote-only and viewable at the time of the event via https://videocast.nih.gov <https://videocast.nih.gov/> and then archived. **
This session will discuss the remarkable scientific arc of GLP-1, from early efforts to understand gut peptides and glucagon biology, to the identification of the biologically active GLP-1(7-37) sequence as a 31–amino acid incretin with therapeutic potential, to the modern development of GLP-1 receptor agonists as transformative treatments. We will begin by describing foundational work defining active GLP-1 and establishing its insulin-stimulating properties, placing the discoveries in the broader context of incretin biology. Then will address the urgent need for effective therapies for metabolic dysfunction–associated steatohepatitis (MASH), the rationale for using GLP-1 receptor agonists in this disease, key benefits and concerns in clinical use, and ongoing NIH studies aimed at understanding mechanisms of action and predictors of response.
Together, the speakers hope the audience will gain a clear understanding of how fundamental peptide biochemistry led to one of the most consequential therapeutic classes in modern medicine—and what important mechanistic and clinical questions remain.
Svetlana Mojsov <https://www.rockefeller.edu/our-scientists/research-affiliates/1055-svetlana-mojsov/> is the Lulu Chow Wang and Robin Chemers Neustein Research Associate Professor at The Rockefeller University. A recipient of the Breakthrough Prize in Life Sciences (2025) and Lasker-DeBakey Clinical Medical Research Award (2024), Mojsov has been central to identifying the biologically active form of GLP-1, GLP-1(7-37), and demonstrating its role as an incretin capable of stimulating insulin secretion. Her discoveries laid critical groundwork for the development of GLP-1–based therapies for type 2 diabetes and obesity.
Yaron Rotman <https://irp.nih.gov/pi/yaron-rotman> is an NIH senior investigator and chief of the Liver & Energy Metabolism Section in the NIDDK Liver Diseases Branch and an attending hepatologist at the NIH Clinical Center. His research focuses on mechanistic and translational studies of metabolic dysfunction–associated steatotic liver disease, using clinical trials, human genetics, and experimental models to uncover pathways of hepatic fat accumulation and injury.
With speakers like this, as always, be prepared to be dazzled and demystified
